Impax Laboratories, Inc.
IPXL
IPXL was delisted on the 4th of May, 2018.
162 hedge funds and large institutions have $1.42B invested in Impax Laboratories, Inc. in 2014 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 53 increasing their positions, 74 reducing their positions, and 39 closing their positions.
812% more call options, than puts
Call options by funds: $20.9M | Put options by funds: $2.29M
12% less funds holding
Funds holding: 185 → 162 (-23)
24% less capital invested
Capital invested by funds: $1.85B → $1.42B (-$436M)
28% less repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 74
56% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 39
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SPC
Slate Path Capital
New York
|
+$59.7M |
| 2 |
O
OrbiMed
New York
|
+$25.4M |
| 3 |
TGI
Tradewinds Global Investors
Los Angeles,
California
|
+$17.3M |
| 4 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
+$16.5M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$9.79M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$38.2M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$37.9M |
| 3 |
GC
Guggenheim Capital
Chicago,
Illinois
|
-$21M |
| 4 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$16M |
| 5 |
Norges Bank
Oslo,
Norway
|
-$15.3M |
IPXL Hedge Fund Activity: Q3 2014 in Review
162 of the 3,448 institutional investors tracked by Wall St. Rank reported a position in Impax Laboratories, Inc. (IPXL) for Q3 2014, worth a combined $1.42B — down 24% from $1.85B a quarter earlier.
Sellers outnumbered buyers: 39 funds closed out of IPXL and 17 opened new positions — a net loss of 22 holders — while 74 trimmed existing stakes and 53 added.
The largest buyer was Slate Path Capital, opening a new position worth an estimated $59.7M. The largest seller was Lord, Abbett & Co, exiting entirely with an estimated $38.2M sold.
- 162 institutional investors held Impax Laboratories, Inc. (IPXL) as of Q3 2014, down from 185 in Q2 2014.
- Funds reported $1.42B of Impax Laboratories, Inc. stock for Q3 2014, down 24% quarter-over-quarter.
- 17 funds opened new Impax Laboratories, Inc. positions in Q3 2014 and 39 closed out, a net change of -22 holders.
- The largest Impax Laboratories, Inc. buyer in Q3 2014 was Slate Path Capital, an estimated $59.7M added.
- The largest Impax Laboratories, Inc. seller in Q3 2014 was Lord, Abbett & Co, an estimated $38.2M sold.
Based on aggregated 13F filings for Q3 2014.